Verificando…
Traduzido automaticamente. Doses e advertências: confira o original em inglês. Ler em inglês
Início / Registado na Nigéria / Clamicin 500 Capsule

Clamicin 500 Capsule

NAFDAC Reg. No. 04-6793 · Drug

Registered with NAFDAC. Registration activeAs of 30 October 2026 · synced automatically from official sources.
Product
Clamicin 500 Capsule
Número NAFDAC
04-6793
Princípio ativo
Lincomycin (Lincomycin Hydrochloride)
Dosagem
500 mg
Forma
Capsule
Tamanho da embalagem
3 x 4's (in PVC/Aluminum foil blisters)
Manufacturer
Not listed
Applicant (holder)
Clarion Medicals Limited
Approved
27 Jun 2024
Situação
Active View on NAFDAC ↗
Registro válido até
26 Jun 2029
Alertas da OMS
None found
Community reports
None
Times checked
0

About the medicine: Lincomycin: uses, dosage and brands worldwide

What we found

  • Clamicin 500 Capsule is on the NAFDAC register with an active registration (04-6793). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Clamicin 500 Capsule

O que diz a bula oficial. Se um médico receitou, siga a receita. Se a bula da sua caixa for diferente, vale a da sua caixa.

Advertência grave: Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including lincomycin and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. …
Para quem é

Lincomycin injection is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. …

Como tomar e com que frequência
  • If significant diarrhea occurs during therapy, lincomycin should be discontinued. (see BOXED WARNING ) INTRAMUSCULAR - Adults: Serious infections —600 mg (2 mL) intramuscularly every 24 hours
  • More severe infections —600 mg (2 mL) intramuscularly every 12 hours or more often
  • Pediatric patients over 1 month of age: Serious infections —one intramuscular injection of 10 mg/kg (5 mg/lb) every 24 hours
  • More severe infections — one intramuscular injection of 10 mg/kg (5 mg/lb) every 12 hours or more often
  • INTRAVENOUS - Adults: The intravenous dose will be determined by the severity of the infection
  • For serious infections doses of 600 mg of lincomycin (2 mL of lincomycin) to 1 gram are given every 8 to 12 hours
  • For more severe infections these doses may have to be increased
  • In life-threatening situations daily intravenous doses of as much as 8 grams have been given
  • Intravenous doses are given on the basis of 1 gram of lincomycin diluted in not less than 100 mL of appropriate solution (see PHYSICAL COMPATIBILITIES) and infused over a period of not less than one hour
  • Dose Vol
  • Diluent Time 600 mg 100 mL 1 hr 1 gram 100 mL 1 hr 2 grams 200 mL 2 hr 3 grams 300 mL 3 hr 4 grams 400 mL 4 hr These doses may be repeated as often as required to the limit of the maximum recommended daily dose of 8 grams of lincomycin
  • Pediatric patients over 1 month of age: 10 to 20 mg/kg/day (5 to 10 mg/lb/day) depending on the severity of the infection may be infused in divided doses as described above for adults. …
Children
  • Lincomycin injection contains benzyl alcohol as a preservative
  • Benzyl alcohol has been associated with a fatal “Gasping Syndrome” in premature
  • Infants
  • See WARNINGS
  • Safety and effectiveness
  • In pediatric patients below the age of one month have not been established. (see DOSAGE AND ADMINISTRATION )
While you are taking it
  • Patients should be counseled that antibacterial drugs including lincomycin should only be used to treat bacterial infections
  • They do not treat viral infections (e.g., the common cold)
  • When lincomycin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed
  • Skipping doses or not completing the full course of therapy may decrease the effectiveness of the immediate treatment and increase the likelihood that bacteria will develop resistance and will not be treatable by lincomycin or other antibacterial drugs in the future. …
Talk to a doctor first if

Lincomycin injection is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin.

Medicines it may not mix with

Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents; therefore, it should be used with caution in patients receiving such agents.

Warnings

See BOXED WARNING . Clostridioides difficile associated diarrhea Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Lincomycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. …

Possíveis efeitos colaterais

The following adverse reactions have been reported with the use of lincomycin. Gastrointestinal disorders Diarrhea, nausea, vomiting, glossitis, stomatitis, abdominal pain, abdominal discomfort † , anal pruritus Skin and subcutaneous tissue disorders Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, dermatitis bullous, dermatitis exfoliative, erythema multiforme (see WARNINGS ), rash, urticaria, pruritus Infections and infestations Vaginal infection, pseudomembranous colitis, Clostridioides difficile colitis (see WARNINGS ) Blood and lymphatic system disorders Pancytopenia, agranulocytosis, aplastic anemia, leukopenia, neutropenia, thrombocytop …

Pregnancy and breastfeeding

Pregnancy There are no adequate and well-controlled studies in pregnant women. Lincomycin Sterile Solution contains benzyl alcohol as a preservative. Benzyl alcohol can cross the placenta. See WARNINGS . Lincomycin should be used during pregnancy only if clearly needed. …

If you take too much

Serum concentrations of lincomycin are not appreciably affected by hemodialysis and peritoneal dialysis.

Se esquecer uma dose

Tome assim que lembrar, a menos que esteja quase na hora da próxima dose. Nesse caso, pule a dose esquecida. Nunca tome duas doses de uma vez para compensar. Confira a bula, pois alguns medicamentos são diferentes.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-08-04.

Label for lincomycin (lincomycin hydrochloride), the active ingredient registered with NAFDAC.

Check your pack of Clamicin 500 Capsule

Add the expiry date on your pack for a full Trust Score.

Ou tire fotos da caixa
Restam 3 verificações grátis hoje Fontes oficiais: FDA dos EUA · EMA (UE) · NAFDAC · alertas da OMS

About Clamicin 500 Capsule

What is in Clamicin 500 Capsule?

Clamicin 500 Capsule contains Lincomycin (Lincomycin Hydrochloride) (500 mg), as capsule, according to its NAFDAC registration record.

Is Clamicin 500 Capsule registered with NAFDAC?

Yes. Clamicin 500 Capsule is listed on the NAFDAC register under registration number 04-6793, and its registration is active as of 30 October 2026.

Has Clamicin 500 Capsule been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Clamicin 500 Capsule in our automatically synced alert list.

How can I check that my pack of Clamicin 500 Capsule is genuine?

Run a free authenticity scan with the NAFDAC number 04-6793, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Clamicin 500 Capsule?

Follow your prescription or the leaflet in your pack. The official label says: If significant diarrhea occurs during therapy, lincomycin should be discontinued. (see BOXED WARNING ) INTRAMUSCULAR - Adults: Serious infections —600 mg (2 mL) intramuscularly every 24 hours. More severe infections —600 mg (2 mL) intramuscularly every 12 hours or more often. Pediatric patients over 1 month of age: Serious infections —one intramuscular injection of 10 mg/kg (5 …

What is Clamicin 500 Capsule used for?

Lincomycin injection is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the p (Summarised from the official U.S. FDA label for lincomycin (lincomycin hydrochloride). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Clamicin 500 Capsule? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.